<DOC>
	<DOCNO>NCT00155714</DOCNO>
	<brief_summary>The aim trial evaluate efficacy type-5 phosphodiesterase inhibitor ( sildenafil ) primary secondary pulmonary hypertension</brief_summary>
	<brief_title>Efficacy Type-5 Phosphodiesterase Inhibitors Primary Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>Patients primary secondary pulmonary hypertension recruit admitted ICUs National Taiwan University Hospital . Each patient undergo Swan-Ganz catheterization hemodynamic monitoring administration sildenafil . Efficacy inhale NO Iloprost also compare .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Phosphodiesterase Inhibitors</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients primary secondary pulmonary arterial hypertension Unstable patient patient allergy sildenafil</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>type-5 phosphodiesterase Inhibitors</keyword>
	<keyword>Sildenafil</keyword>
</DOC>